Archive for the 'Liver Disease' Category
Acutely Damaged Livers May Be Repaired Via Transplanted Hepatocytes
A research team from the National Taiwan University Hospital has evaluated the efficiency of transplanted hepatocyte (liver) cells in animal models severely damaged by two kinds of chemical toxicity to see whether and how transplanted hepatocytes were able to efficiently repopulate the toxin-induced, severely damaged livers…Original post by Diabetes Mine
No commentsCell-Culture And Animal Tests Show Antiviral Could Provide Protection Against HIV, Ebola, Hepatitis C, Herpes And More
The development of antibiotics gave physicians seemingly miraculous weapons against infectious disease. Effective cures for terrible afflictions like pneumonia, syphilis and tuberculosis were suddenly at hand. Moreover, many of the drugs that made them possible were versatile enough to knock out a wide range of deadly bacterial threats…Original post by Diabetes Mine
No commentsMinimally Invasive Adult Liver Donation For Pediatric Transplantation Available Exclusively At NewYork-Presbyterian Morgan Stanley Children’s Hospital
NewYork-Presbyterian Morgan Stanley Children’s Hospital is the only medical center in the United States to offer minimally invasive liver donation for pediatric transplantation. Surgeons use a laparoscopic technique to remove a section of liver from a living donor for implantation in a pediatric patient — typically a parent donating to their child…Original post by Six Until Me.
No commentsConatus Pharmaceuticals Initiates Phase II Clinical Trial In Combination With Pegylated Interferon And Ribavirin For The Treatment Of Hepatitis C
Conatus Pharmaceuticals Inc. announced the initiation of a Phase II clinical trial evaluating CTS-1027 in combination with pegylated interferon (Pegasys®) and ribavirin (Copegus®) in refractory HCV patients. Antiviral activity, safety and tolerability of the triple combination will be assessed after up to 48 weeks of therapy…Original post by Diabetes Mine
No commentsAethlon Medical Discloses Hepatitis C (HCV) Treatment Publication
Aethlon Medical, Inc. (OTC Bulletin Board: AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, disclosed that its Hemopurifier® is the subject of a publication in the latest issue of the Journal of Blood Purification…Original post by Consumer Reports Health Blog
No commentsBeyond The Ice: Technique For Preserving Pre-Transplant Livers Promises To Improve Patient Outcomes And Expand The Organ Pool
Preserving organs on ice prior to transplantation, an approach known as cold storage or CS, has been the standard practice in liver transplant for 20 years. Now there is new evidence that a technique called hypothermic machine perfusion (HMP) may offer an improvement, according to the first-ever study comparing the impact of the two techniques on transplant outcomes…Original post by Diabetes Mine
No commentsParadigm Shift In Hepatitis C Testing May Curb The Numbers Affected, Says Expert
The Institute of Medicine, a branch of the US National Academy of Sciences, is urging healthcare providers to take steps to battle liver-damaging hepatitis B and C, which are often overlooked viruses. Surprisingly, hepatitis B and C together infect three to five times more Americans than the AIDS virus does…Original post by Diabetes Mine
No commentsNews From The American Journal Of Pathology, February 2010
Environmental Cues Lead to Breast Cancer A group led by Dr. Peter Lloyd Jones at the University of Dundee, Dundee, Scotland; the University of Colorado Denver, Aurora, CO; and the University of Pennsylvania, Philadelphia, PA has demonstrated that tenascin-C affects proto-oncogene function in breast cancer…Original post by Diabetes Mine
No commentsReal-World Treatment Patterns, Non-Adherence, And Costs In Chronic Hepatitis C
Failure to adhere to treatment regimens is a common problem among patients treated for chronic hepatitis C virus (HCV). The costs associated with non-adherence are high, according to a study appearing in an upcoming issue of Value in Health…Original post by Diabetes Mine
No commentsAnadys Pharmaceuticals Provides Progress Update On Phase II Study Of ANA598 In Hepatitis C Patients
Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced that ANA598 dosing has been completed in the first dose cohort, 200 mg bid, in an ongoing Phase II study of ANA598 in combination with pegylated interferon and ribavirin (SOC) in HCV patients. Anadys expects to receive 12-week safety and antiviral response data for the 200 mg bid cohort in the first quarter of 2010…Original post by Fade Library
No comments